首页> 外文期刊>Trials >The TEAM trial: Safety and efficacy of endovascular treatment of unruptured intracranial aneurysms in the prevention of aneurysmal hemorrhages: A randomized comparison with indefinite deferral of treatment in 2002 patients followed for 10 years
【24h】

The TEAM trial: Safety and efficacy of endovascular treatment of unruptured intracranial aneurysms in the prevention of aneurysmal hemorrhages: A randomized comparison with indefinite deferral of treatment in 2002 patients followed for 10 years

机译:TEAM试验:血管内治疗颅内动脉瘤破裂对预防动脉瘤出血的安全性和有效性:随机比较2002年无限期推迟治疗的患者,随访10年

获取原文
           

摘要

The management of patients with unruptured aneurysms remains controversial. Patients with unruptured aneurysms may suffer intracranial haemorrhage, but the incidence of this event is still debated; endovascular treatment may prevent rupture, but involves immediate risks. Hence, the balance of risks and benefits of endovascular treatment is uncertain. Here, we report the design of the TEAM trial, the first international, randomized, controlled trial comparing conservative management with endovascular treatment. Primary endpoint is mortality and morbidity (modified Rankin Score ≥ 3) from intracranial haemorrhage or treatment. Secondary endpoints include incidence of hemorrhagic events, morbidity related to endovascular coiling, morphological results, overall clinical outcome and quality of life. Statistical tests compare between probabilities at 5- and 10-years of 1/mortality from haemorrhage related to the lesion, excluding per-operative complications; 2/mortality from haemorrhage or from complications of treatment; 3/combined disease or treatment related mortality and morbidity in the absence of other causes of death or disability. The study will be conducted in 60 international centres and will enrol 2,002 patients equally divided between the two groups, a size sufficient to achieve 80% power at a 0.0167 significance to detect differences in 1) disease or treatment-related poor outcomes from 7–9% to 3–5%; 2) overall mortality from 16 to 11%. Duration of the study is 14 years, the first three years being for patient recruitment plus a minimum of 10 years of follow-up. The TEAM trial thus offers a means to reconcile the introduction of a new approach with the necessity to acknowledge uncertainties. Trial registration Current Controlled Trials ISRCTN62758344 http://www.controlled-trials.com webcite
机译:动脉瘤未破裂患者的治疗仍存在争议。动脉瘤未破裂的患者可能会发生颅内出血,但该事件的发生率仍存在争议。血管内治疗可预防破裂,但存在直接风险。因此,血管内治疗的风险与收益之间的平衡尚不确定。在这里,我们报告TEAM试验的设计,这是第一项比较保守治疗与血管内治疗的国际性,随机,对照试验。主要终点是颅内出血或治疗引起的死亡率和发病率(Rankin得分≥3)。次要终点包括出血事件的发生率,与血管内卷曲相关的发病率,形态学结果,总体临床结局和生活质量。统计测试比较了与病变有关的出血的1 /死亡率在5年和10年的概率,不包括手术并发症。 2 /因出血或治疗并发症而死亡; 3 /没有其他死亡或残疾原因的综合疾病或治疗相关的死亡率和发病率。该研究将在60个国际中心进行,将招募2,002名患者,两组患者均分,其大小足以以0.0167的显着性获得80%的功效,以发现1)7-9岁患者疾病或与治疗相关的不良结局%到3–5%; 2)总死亡率从16%上升到11%。研究时间为14年,前三年为患者招募,另加至少10年的随访。因此,TEAM试验提供了一种手段,可以调和采用新方法并承认不确定性的必要性。试用注册当前对照试验ISRCTN62758344 http:// www。受控-trials.com网站

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号